콘텐츠로 건너뛰기
Merck
  • Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.

Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.

Diabetes research and clinical practice (2018-07-22)
Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel
초록

The two dipeptidyl peptidase (DPP)-4 inhibitors, linagliptin and sitagliptin, were shown to exert different binding kinetics in vitro. Twenty-four hours after oral dosing particularly in vivo inhibition of renal-specific DPP-4 activity was more sustained in Sprague Dawley rats after exposure to linagliptin than it was after sitagliptin.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
Gly-Pro 4-methoxy-β-naphthylamide, dipeptidylpeptidase IV substrate